| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H20N4O2 |
| Molecular Weight | 264.3235 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O
InChI
InChIKey=MRWQRJMESRRJJB-UHFFFAOYSA-N
InChI=1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3
Pentifylline is an active vasodilating substance which does not affect blood sugar levels. Pentifylline inhibits the soluble and the particulate cyclic AMP phosphodiesterases from bovine platelets and rat brain ATPase. The inhibition of ATPase by pentifylline was not influenced by the change in Na /K ratio. Pentifylline in combination with Nicotinic acid indicated for the treatment of Cerebral circulatory disorders and Circulatory disorders of the eye. Pentifylline is well tolerated but it is recommended that blood pressure be monitored and if there is a severe drop in blood pressure, a drip infusion of plasma expander be administered. Coagulation states should also be closely watched.
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Tox targets
PubMed
Patents
Sample Use Guides
Cerebral and peripheral circulatory disorders: 400 mg one tablet twice daily (Initial and normal dose) or 400 mg tablet daily for as long as necessary (Maintenance dose).
Circulatory disorders of the eye: 400 mg two or three times daily (Initial and normal dose) or 400 mg once or twice daily for as long as necessary (Maintenance dose).
Route of Administration:
Oral
The secretion of type-I collagen COOH-terminal peptide (PIP) into the culture medium in the presence of pentifylline (PTF) was significantly lower than that in the presence of pentoxifylline (PTX) at concentrations of 10-1000 ug/ml; its level in cell lysate in the presence of PTX at concentrations of 10-100 ug/ml.
ACTIVE MOIETY
